Bills · 2021-2022 Regular Session
Relating to: newborn screening for Krabbe disease and requiring evaluation of additional lysosomal storage disorders for mandatory screening. (FE)
Disease Health services department of — Health Hospitals and health care facilities Maternal and infant care Medical service — Occupations Medicine Physician
- Introduced, stopped here
- Passes Senate, not reached
- Passes Assembly, not reached
- Governor signs, not reached
- Law, not reached
Unfamiliar terms? Glossary
What this bill does
Plain-language analysis by the nonpartisan Legislative Reference Bureau
This bill requires that, in addition to the other congenital and metabolic
disorders for which testing is currently required under rules established by the
Department of Health Services, the attending physician, nurse-midwife, or in
certain circumstances, other birth attendant, must ensure that every infant born
undergoes testing for globoid cell leukodystrophy, also known as Krabbe disease,
which is a lysosomal storage disorder. Current law requires that an attending
physician or nurse-midwife ensure that every infant born undergoes testing for
certain congenital and metabolic disorders prior to the infant's discharge from the
hospital or maternity home. For infants born elsewhere, the attending physician,
nurse-midwife, or other birth attendant must ensure that the infant is tested within
a week of birth. As authorized by current law, DHS specifies by rule the congenital
and metabolic disorders for which newborn infants are to be screened. Current law
allows an exception to the testing requirement if the parents or legal guardian object
on the basis of a conflict with religious tenets and practices or with their personal
convictions.
Under the bill, for infants born in a hospital or maternity home, the attending
physician or nurse-midwife must ensure testing for Krabbe disease is completed
before the infant is discharged or within one week of birth, if the infant has not yet
been discharged. For births occurring outside a hospital or maternity home setting,
the attending physician, nurse-midwife, or other birth attendant must ensure
testing is done within one week of birth. The parental objection exemption under
current law also applies to the testing required under this bill.
The bill also requires DHS to evaluate on a biennial basis the appropriateness
of mandatory newborn testing for lysosomal storage disorders in addition to the
testing for Krabbe disease. If DHS determines that testing for one or more other
lysosomal storage disorders is appropriate, DHS may promulgate rules adding to the
list of disorders for which newborn testing is required.
What it would cost
Fiscal estimates filed by state agencies, as official PDFs
Sponsors
Votes
Senate: Report passage recommended by Committee on Health, Ayes 3, Noes 2
Passed 3–2 Mar 19, 2021 official source full pageNo individual roll call was recorded for this vote. Committee votes and some older sessions record totals only.
Full history
- Mar 10, 2021 · Senate
Introduced by Senators Testin, Marklein, Darling and L. Taylor; cosponsored by Representatives Novak, Tranel, Dittrich, Kitchens, Rozar, Shankland, Skowronski, Spiros, Swearingen, Tauchen, Tusler, Vorpagel and Subeck
- Mar 10, 2021 · Senate
Read first time and referred to Committee on Health
- Mar 16, 2021 · Senate
Senator Bernier added as a coauthor
- Mar 17, 2021 · Senate
Public hearing held
- Mar 18, 2021 · Senate
Fiscal estimate received
- Mar 19, 2021 · Senate
Executive action taken
- Mar 19, 2021 · Senate
Report passage recommended by Committee on Health, Ayes 3, Noes 2
- Mar 19, 2021 · Senate
Available for scheduling
- Apr 20, 2021 · Senate
Fiscal estimate received
- Apr 29, 2021 · Senate
Senator Roys added as a coauthor
- Jun 8, 2021 · Senate
Senate Amendment 1 offered by Senator Testin
- Oct 11, 2021 · Senate
Senate Amendment 2 offered by Senator Testin
- Jan 13, 2022 · Senate
Representative Shankland withdrawn as a cosponsor
- Mar 15, 2022 · Senate
Failed to pass pursuant to Senate Joint Resolution 1